Zimmer Biomet Holdings, Inc. $ZBH Shares Bought by Boston Trust Walden Corp

Boston Trust Walden Corp increased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 45.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 693,322 shares of the medical equipment provider’s stock after buying an additional 215,249 shares during the quarter. Boston Trust Walden Corp owned about 0.35% of Zimmer Biomet worth $63,238,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of ZBH. Ameriprise Financial Inc. increased its holdings in Zimmer Biomet by 236.0% in the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after buying an additional 3,208,596 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Zimmer Biomet by 251.3% during the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock valued at $235,571,000 after buying an additional 1,488,918 shares in the last quarter. Nuveen LLC purchased a new position in shares of Zimmer Biomet during the 1st quarter valued at approximately $155,891,000. Alyeska Investment Group L.P. purchased a new position in Zimmer Biomet in the 1st quarter valued at $101,294,000. Finally, Dodge & Cox lifted its holdings in Zimmer Biomet by 2.3% in the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock valued at $2,214,305,000 after purchasing an additional 446,018 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

ZBH stock opened at $95.13 on Tuesday. The business has a 50 day moving average price of $101.36 and a 200 day moving average price of $98.03. The stock has a market cap of $18.85 billion, a price-to-earnings ratio of 23.15, a PEG ratio of 2.18 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $114.72. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. The firm had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s payout ratio is currently 23.36%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.70% of the company’s stock.

Analyst Upgrades and Downgrades

ZBH has been the topic of several analyst reports. BTIG Research lifted their price target on Zimmer Biomet from $118.00 to $122.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. Stifel Nicolaus raised their price objective on Zimmer Biomet from $115.00 to $118.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Raymond James Financial raised their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Finally, Evercore ISI cut their price objective on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research report on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $113.16.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.